Chul Kim: March has been fruitful and rewarding, as we launched two IITs of ADC back to back!

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared on X/Twitter:

“March has been fruitful and rewarding, as we launched two IITs of ADC back to back!

1. Vobramitamab duocarmazine (B7-H3 ADC) for ES-SCLC, inclusive of patients with transformed SCLC (NCT06227546),

2. Sacituzumab govitecan for thymic epithelial tumors (NCT06248515).”

Source: Chul Kim/X

ADCs cancer Chul Kim ES-SCLC Georgetown University investigator-initiated trial OncoDaily Oncology Sacituzumab govitecan SCLC small cell lung cancer thymic epithelial tumors Vobramitamab duocarmazine